BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12060121)

  • 1. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.
    Galmarini CM; Thomas X; Calvo F; Rousselot P; Rabilloud M; El Jaffari A; Cros E; Dumontet C
    Br J Haematol; 2002 Jun; 117(4):860-8. PubMed ID: 12060121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential mechanisms of resistance to cytarabine in AML patients.
    Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
    Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia.
    Galmarini CM; Graham K; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Mackey JR; Dumontet C
    Blood; 2001 Sep; 98(6):1922-6. PubMed ID: 11535530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.
    Galmarini CM; Thomas X; Graham K; El Jafaari A; Cros E; Jordheim L; Mackey JR; Dumontet C
    Br J Haematol; 2003 Jul; 122(1):53-60. PubMed ID: 12823345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
    Hubeek I; Stam RW; Peters GJ; Broekhuizen R; Meijerink JP; van Wering ER; Gibson BE; Creutzig U; Zwaan CM; Cloos J; Kuik DJ; Pieters R; Kaspers GJ
    Br J Cancer; 2005 Dec; 93(12):1388-94. PubMed ID: 16333246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Meijerink JP; Ebus ME; Peters GJ; Noordhuis P; Janka-Schaub GE; Armstrong SA; Korsmeyer SJ; Pieters R
    Blood; 2003 Feb; 101(4):1270-6. PubMed ID: 12406912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
    Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA
    Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia.
    Jahns-Streubel G; Reuter C; Auf der Landwehr U; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
    Blood; 1997 Sep; 90(5):1968-76. PubMed ID: 9292531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic factors influencing cytarabine therapy.
    Lamba JK
    Pharmacogenomics; 2009 Oct; 10(10):1657-74. PubMed ID: 19842938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
    Braess J; Voss S; Jahns-Streubel G; Schoch C; Haferlach T; Kern W; Keye S; Schleyer E; Hiddemann W
    Br J Haematol; 2000 Jul; 110(1):170-9. PubMed ID: 10930995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukaemia cell drug resistance and prognostic factors in AML.
    Nørgaard JM; Olesen G; Kristensen JS; Pedersen B; Hokland P
    Eur J Haematol; 1999 Oct; 63(4):219-24. PubMed ID: 10530409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
    Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
    Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia.
    Yin B; Kogan SC; Dickins RA; Lowe SW; Largaespada DA
    Exp Hematol; 2006 May; 34(5):631-41. PubMed ID: 16647569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
    Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T
    Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.
    Schröder JK; Kirch C; Seeber S; Schütte J
    Br J Haematol; 1998 Dec; 103(4):1096-103. PubMed ID: 9886326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
    Tina E; Prenkert M; Höglund M; Paul C; Tidefelt U
    Oncol Rep; 2009 Dec; 22(6):1527-31. PubMed ID: 19885609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study.
    Wan H; Zhu J; Chen F; Xiao F; Huang H; Han X; Zhong L; Zhong H; Xu L; Ni B; Zhong J
    J Exp Clin Cancer Res; 2014 Nov; 33(1):90. PubMed ID: 25398670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.